1. Home
  2. MLCO vs MLYS Comparison

MLCO vs MLYS Comparison

Compare MLCO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Melco Resorts & Entertainment Limited

MLCO

Melco Resorts & Entertainment Limited

HOLD

Current Price

$5.36

Market Cap

2.2B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.68

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLCO
MLYS
Founded
2003
2019
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2006
2023

Fundamental Metrics

Financial Performance
Metric
MLCO
MLYS
Price
$5.36
$26.68
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$10.10
$48.67
AVG Volume (30 Days)
2.2M
2.0M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.42
N/A
Revenue Next Year
$4.37
N/A
P/E Ratio
$12.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.07
$12.59
52 Week High
$10.15
$47.65

Technical Indicators

Market Signals
Indicator
MLCO
MLYS
Relative Strength Index (RSI) 45.09 49.44
Support Level $5.33 $25.40
Resistance Level $5.71 $30.85
Average True Range (ATR) 0.22 1.20
MACD -0.03 0.28
Stochastic Oscillator 29.38 81.48

Price Performance

Historical Comparison
MLCO
MLYS

About MLCO Melco Resorts & Entertainment Limited

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: